WELL Health Subsidiary WELLSTAR Provides Corporate Update Reflecting Improved Guidance and a Strong Acquisition Pipeline
WELLSTAR continues to demonstrate strong growth and execution, fueled by accelerating demand for its digital health solutions and steady progress across its platform. The business is tracking ahead of internal expectations and has updated its guidance for fiscal 2025 to over $74 million (1) in revenue and $22 million (1) in Adjusted EBITDA (2). WELLSTAR is also expected to end the year with total annual recurring revenue (ARR) of approximately $62 million and an exit ARR (3) of approximately $80 million, supported by robust organic expansion, continued adoption of its AI-powered tools, and inclusive of completing three acquisitions that are currently in signed LOI stage.
Amir Javidan, CEO of WELLSTAR commented, 'We've had an excellent first half to 2025 as both our organic and inorganic growth engines are levelling up and are poised to deliver an outstanding, breakout performance for WELLSTAR in 2025. At the beginning of the year, we set an ambitious goal of reaching $100M in revenues on a run-rate basis in the next couple of years and based on the latest forecasts, we believe we may be approaching that goal a few quarters earlier than previously anticipated. Our current goal for year-end exit ARR for fiscal 2025 is $80 million which would represent a 50% increase over last year's exit ARR figure.
Darren Hoegler, CFO of WELLSTAR commented, 'This upward revision reflects stronger-than-expected traction across WELLSTAR's core product suite as well as strong execution in the company's capital allocation program. We currently have three signed LOIs with targets that all deliver high-margin SaaS solutions and would be highly accretive to our business. I'm also pleased to report that the two acquisitions that were completed in Q4 2024 are both operating well and tracking in alignment with or ahead of our plan. Our objective is to ensure disciplined execution and that the company continues to be positioned as a category leader in Canadian digital health, delivering durable, capital-efficient growth with significant operating leverage over time.'
Three LOIs Executed as WELLSTAR Executes on Deep Acquisition Pipeline
WELLSTAR has executed three letters of intent (LOIs) for acquisitions that are expected to contribute approximately $15 million in ARR, $16 million in revenue, and over $5 million in Adjusted EBITDA on an annualized run-rate basis. These prospective additions reflect WELLSTAR's continued focus on disciplined, accretive growth through the acquisition of complementary digital health assets that strengthen its core platform and expand its national footprint.
The acquisitions are aligned with WELLSTAR's long-term strategy to build a technology-enabled healthcare infrastructure that is efficient, scalable, and outcomes-driven. Each target adds strategic value by extending WELLSTAR's clinician enablement capabilities. The integrated nature of WELLSTAR's platform enables smooth onboarding and operational alignment, allowing new assets to benefit from shared infrastructure and drive incremental impact across the broader business.
WELLSTAR continues to advance a deep and well-qualified acquisition pipeline, with additional opportunities under review.
Strong Early Traction for Nexus AI with Clinicians Nationwide
Since its launch on May 7, 2025, Nexus AI has seen strong adoption, with over 2,400 providers signed up across primary care clinics, hospitals, and regional health authorities. Nexus AI's first feature, an ambient medical scribe for real-time clinical documentation, is already demonstrating meaningful value for providers by reducing administrative burden and cognitive load. AI medical scribe technology has been shown to save providers up to two hours per day in charting and documentation (4).
Nexus AI serves as the central platform for WELLSTAR's expanding suite of AI-powered capabilities, including disease detection, medical coding and billing automation, and clinical decision support. Its compatibility with Canada's leading EMRs positions it as a scalable infrastructure layer for modern, intelligent healthcare delivery.
Clinician engagement with Nexus AI is expected to contribute to WELLSTAR's recurring SaaS revenue and margin profile as deployments scale. Just as importantly, the platform's ability to orchestrate complex clinical workflows in an intuitive and context-aware way supports broader system-level efficiency and provider satisfaction.
As a pre-qualified vendor of the Canada Health Infoway AI Scribe Program, eligible primary care clinicians across Canada will receive a fully-funded license for 12 months of Nexus AI. WELLSTAR recognizes this as a transformative opportunity to advance Canada's vision of connected care, where AI-enabled technologies reduce physician burnout, improve patient experience, and allow providers to focus more on engagement and less on documentation. By delivering accurate, secure documentation at the point of care, Nexus AI empowers providers to reclaim meaningful patient connections and supports a broader effort to integrate AI technologies that promote more connected, patient-centred care.
Footnotes:
WELLSTAR's guidance of $74 million in revenue and $22 million in Adjusted EBITDA in fiscal 2025 includes the impact from the three LOIs noted herein which will contribute approximately $4 million in revenue and $1 million in Adjusted EBITDA for inclusion in fiscal 2025. Note that this figure does not include certain shared services that are provided by WELL Health to WELLSTAR.
Adjusted EBITDA is a non-GAAP financial measure. Please refer to WELL's most recent Management's Discussion and Analysis (MD&A), available under the Company's profile on SEDAR+ at www.sedarplus.ca, for further details including definitions and reconciliations to the nearest IFRS measure.
Exit ARR or Annual Recurring Revenue is based on the Company's revenue run-rate or ARR as annualized based on the last quarter of the year. The projected Exit ARR of approximately $80 million includes contribution from the three LOIs noted herein.
Source: OntarioMD, AI scribes show promising results in helping family doctors and nurse practitioners spend more time with patients and less time on paperwork, September 11, 2024. https://www.ontariomd.ca/pages/ai-scribes-promising-results.aspx
WELL HEALTH TECHNOLOGIES CORP.
Per: 'Hamed Shahbazi'
Chief Executive Officer, Chairman and Director
WELL Health Technologies Inc.
WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 210 clinics supporting primary care, specialized care, and diagnostic services. In the United States, WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about the Company, please visit: www.well.company.
Forward-Looking Statements
Certain statements in this press release, constitute 'forward-looking information' and 'forward looking statements' (collectively, 'forward looking statements') within the meaning of applicable Canadian securities laws, including the guidance related to revenue and adjusted EBITDA, and the expected pipeline of future acquisition targets (and the associated run-rate revenue). Forward-looking statements are necessarily based upon management's expectations, while considered reasonable by WELL as of the date of such statements, are outside of WELL's control and are inherently subject to business, economic and other uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to the ability to continue to offer its products and services, complete the acquisitions, and the acquisition companies having the expected revenue and Adjusted EBITDA profiles based on WELL's diligence.
Known and unknown risk factors, many of which are beyond the control of WELL could cause the actual plans to differ materially from the results implied by such forward-looking statements. Such risk factors include losing customers to competitors, cybersecurity threats which prevent WELLSTAR from being able to continually offer its products, not completing the three acquisitions discussed above, and the other risks discussed under the section entitled 'Risk Factors' in WELL's most recent annual information form, which is available under the Company's respective SEDAR+ profile at www.sedarplus.ca which could affect WELL's and WELLSTAR's business. The risk factors are not intended to represent a complete list of the factors that could affect WELL or WELLSTAR and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. WELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
26 minutes ago
- Time Business News
How CNC Tube Bending Solves Common Manufacturing Problems
Manufacturing is all about moving parts—literally and metaphorically. From the quick turnaround to intricate part design, businesses are always under pressure to go faster, cheaper, and better. In today's fast-paced world, a small issue can lead to complete slowdowns. Tube bending is just one place where errors can slip in. Off-center bends, irregular angles, waste metal, and human calculation mistakes can all throw a monkey wrench into the works. There's a solution to this problem, and it's making life easier for manufacturers in Canada: CNC tube bending. This process, controlled by a computer, provides accuracy, consistency, and velocity, and enables companies to avoid the frequent aches of the conventional bending technique. Here are the most significant issues that CNC tube bending resolves — and why it is the preferred option in intelligent manufacturing. Problem 1: Variable Bends In older manual or outdated bending equipment, in many instances it is difficult to achieve the same bends on one tube as on another. Minuscule variations in angle, radius, or alignment cause differences that have an impact on how parts fit together. All of these little errors bring about quality control problems, customer dissatisfaction, and more rework in the long term. CNC tube bending eliminates this by employing pre-programmed commands to produce precise, consistent bends. The same tube exits every time, no matter whether batch size is large or small. Monitoring in real-time ensures accuracy from the very first bend to the last. It's particularly critical in sectors such as automotive, HVAC, and construction where a matter of millimetres can be a huge difference. Problem 2: Wasted Material Every error is money — and in tube bending, one mismeasured angle can slice good tubing into useless scrap. Through conventional methods, operators are inclined to rely on guesswork in order to achieve the bend they want when bending intricate shapes or thin-wall tube. CNC machines slash waste by a large degree, getting it right the first time. The computer calculates the perfect bend angles and also allows material stretch and springback compensation. This level of precision utilizes every tube to its maximum potential and improves on the need to over-order material. Canadian businesses that monitor their material costs, particularly those businesses utilizing industries stainless steel or aluminum, see savings increase rapidly. Problem 3: Time-Consuming Setup Tube bending by hand is slow to set up, particularly when switching between projects. Operators must reframe dies, rematerials, and verify accuracy before production begins. Idle time reduces productivity and jams the workflow. Set up is fast and simple in CNC tube bending. Operators can load machine files directly from digital design without manual measuring or adjustment. Job changes take minutes, not hours. This works best for companies that produce multiple part types or run low-volume production. It also minimizes bottlenecks, allowing it to be more on schedule. Problem 4: Shortages of Labor and Training Like most trades, tube bending is a skill and practice issue. But with ongoing labor shortages and turnover in the manufacturing industry, companies cannot find and train qualified operators. CNC tube bending does not require much in terms of large amounts of hands-on experience. Much of the accuracy is looked after by the computer software, and the machines feature easy-to-operate controls. New personnel can quickly pick up the fundamentals and still produce quality work. Canadian manufacturers thus remain efficient even with a thinner or junior workforce. Problem 5: Complex Geometries Product forms of new products frequently include tight radius, complex angles, or multi-plane bends. They are hard and labor-intensive to create by hand. Minor mistakes result in a part failure or expensive redesigns. CNC tube bending has no trouble with complex shapes. Machines can bend tube in various directions, use multiple radii, and manipulate multiple diameters and wall thicknesses. Pre-production of all bends also occurs through the software, thereby detecting problems beforehand. This amenity allows for increasingly innovative, and more productive designs — without sacrificing strength or performance. Problem 6: Repeatability for Long-Term Projects In every other manufacturing industry, particularly automobile, aerospace, and construction, organizations are required to make the same part for months and even years. A slight alteration in quality or size can cause huge issues downstream. CNC bending allows for long-term repeatability. After a design is programmed, it can be stored and reused on subsequent orders. The machine will produce the same part time after time with no change in angle, alignment, or radius. This makes CNC bending ideal for contracts, legacy parts, and product runs of long life. Problem 7: Prototyping and Testing Delays Waiting weeks for a prototype to be hand-bent is long enough to hold up an entire project. If it takes changing a prototype, the whole process is done again from the beginning. It hinders innovation and makes it more difficult for companies to react to new opportunities. CNC tube bending accelerates prototyping. With computer-aided design and rapid setup, new parts can be produced in hours or days instead of weeks. Designers and engineers can rapidly test and re-design parts until finding the optimal fit. Startups, custom fabricators, and R&D departments especially take advantage of this. Problem 8: Rising Cost From raw material and energy to labor and transportation, the cost of manufacturing is on the rise. Businesses must create more value with less. Old bending techniques are commonly outdated. CNC bending saves money all along the line. It saves scrap, increases production, reduces labor requirements, and increases first-pass yield. All of these benefits translate to leaner operations and improved margins. Final Thoughts Manufacturing is full of challenges, but tube bending doesn't have to be one of them. CNC tube bending gives Canadian businesses the precision, speed, and flexibility they need to stay competitive and productive — without the usual headaches. Whether you're building machinery, designing vehicles, or fabricating custom parts, this smart technology ensures your tubes are bent right the first time, every time. No more waste material, No more guesswork, Just clean, reproducible bends that get your projects in on time and your customers smiling— all made possible with pipe bender Canada solutions. TIME BUSINESS NEWS
Yahoo
33 minutes ago
- Yahoo
Carney says a U.S. trade deal without some tariffs is unlikely
Prime Minister Mark Carney said Tuesday U.S. President Donald Trump seems wedded to tariffs and any trade deal with the Americans may include accepting some levies on exports. Speaking to reporters ahead of a cabinet meeting on Parliament Hill about the trade war, Carney said in French that all of Trump's trade agreements to this point have included some tariffs. He said "there's not a lot of evidence right now" that the U.S. is willing to cut a deal without some tariffs included. Indeed, Trump's trade arrangement with the U.K., a country with which the U.S. has a trading surplus, includes a 10 per cent baseline tariff. WATCH | Carney says 'not a lot of evidence' for tariff-free deal: Carney did not say if he's willing to accept tariffs. At last month's G7 summit after a meeting with Trump, Carney said Canada will sign an agreement "that's in Canada's best interest, and only that." Carney said under Trump's current framework Canada has "almost free trade" with the U.S. and that's something he wants to see continue. That's a reference to the tariff exemptions granted to Canadian goods that are compliant with the Canada-U.S.-Mexico Agreement (CUSMA). At the outset of this trade war, the White House estimated some 62 per cent of Canadian exports were not compliant with the trade deal — some companies opted to pay very low duty rates rather than go along with the paperwork required for free access. A recent RBC report suggests compliance has improved since Trump slapped on tariffs and most goods are sold into the U.S. tariff-free. But Carney said Tuesday "there are obviously problems" with the U.S. sectoral tariffs that do apply universally to steel, aluminum, auto exports and the threatened ones on pharmaceuticals, lumber and copper. Those so-called Section 232 tariffs have been particularly damaging to the Canadian economy, leading to job losses and a drop in exports. Those tariffs take their name from the section of a U.S. trade law that allows the president to impose levies on certain goods that are said to threaten "national security." Catherine Cobden, the president and CEO of the Canadian Steel Producers Association, said in an interview Tuesday there's already been a 30 per cent drop in steel production since Trump first imposed his metals tariff. "We need to stabilize the situation for Canada," Carney said. "The government has consistently stood up for Canadian workers and businesses throughout these negotiations. We'll continue to do so. I expect that discussions will intensify between now and the end of the month and we'll be working hard on that." Conservative Leader Pierre Poilievre said Carney's tariff remarks were "another unilateral concession from a man who said he would never back down to the U.S. president." Poilievre was previously critical of Carney's decision to scrap the digital services tax that primarily affected U.S. web giants — a move Trump demanded to continue trade negotiations. Businesswoman Arlene Dickinson, a member of Carney's Council on Canada-U.S. Relations, said tariffs may be inevitable — but there could be a chance to negotiate those away when CUSMA comes up for a review next year. "I can't believe he's going to allow no tariffs to occur because that's just not his style. It's just not what he wants," Dickinson said of Trump in an interview. She said Trump is "bullying" Canada with his constant tariff threats and "autocratic behaviour." Last week, Trump sent a letter to Carney saying he's moving to bump the existing 25 per cent border-related tariff rate on Canadian goods — the tariff that does not apply if a good is CUSMA-compliant — to 35 per cent by Aug. 1. A White House official told CBC News that the CUSMA compliance rule will still apply even if the elevated tariff rate is applied next month. Trump said it's a trade action designed to force Canada to crack down on fentanyl, even as U.S. government data suggests relatively very little of that drug is seized at the northern border. Push to dismantle drug trade Still, the federal government has budgeted more than $1 billion to better police the border for drugs and migrants and law enforcement across the country has been making seizures and arrests as part of a push to dismantle the drug trade. "If Canada works with me to stop the flow of fentanyl, we will, perhaps, consider an adjustment to this letter," Trump said. Speaking to reporters on Monday, Trump said that the letters he's sent to Carney and others are what he sees as the "deal" with the respective countries. "I watched a show this morning and they were talking about, 'Well when's he going to make the deal?' The deals are already made. The letters are the deals. The deals are made. There are no deals to make," Trump said. If that's the case, Canada could hit back with higher counter-tariffs of its own on U.S. goods — something Trump has warned against. When Trump hiked the steel and aluminum tariff to 50 per cent last month, Carney withheld matching that rate saying talks are ongoing to get Canada out from under Trump's tariffs. The prime minister has said Canada's counter-tariffs on U.S. steel and aluminum products will go up if the two sides can't reach a satisfactory deal by month's end. "We will review our response as the negotiations progress," he said.
Business Wire
an hour ago
- Business Wire
Repare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. ('Repare' or the 'Company') (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced it has entered into an exclusive worldwide licensing agreement with Debiopharm International S.A. ('Debiopharm'), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow's standards of care to cure cancer and infectious diseases, for lunresertib, a first-in-class precision oncology PKMYT1 inhibitor. 'The exclusive worldwide licensing agreement with Debiopharm allows for the continued development of lunresertib, a novel PKMYT1 inhibitor, that has demonstrated encouraging results across multiple clinical trials in difficult-to-treat solid tumors. This agreement builds upon the success of Repare and Debiopharm's existing collaboration studying the combination of lunresertib and Debio 0123,' said Steve Forte, President, Chief Executive Officer and Chief Financial Officer of Repare. 'Our recent business development efforts have continued to enable Repare to focus on the advancement of our clinical priorities and sustained value creation. We remain focused on two ongoing Phase 1 clinical trials with readouts expected in the second half of 2025: the LIONS trial evaluating our RP-1664 PLK4 inhibitor and the POLAR trial evaluating our RP-3467 Polθ ATPase inhibitor.' Under the terms of the agreement, Repare will receive a $10 million upfront payment, and is eligible to receive up to $257 million in potential clinical, regulatory, commercial and sales milestones, including up to $5 million in potential near-term payments, and single-digit royalties on global net sales. Repare and Debiopharm entered into a clinical study and collaboration agreement in January 2024 to explore the synergy between lunresertib and Debio 0123, a potential best-in-class, brain penetrant and highly selective WEE1 inhibitor. Debiopharm will assume sponsorship of the MYTHIC study and take over existing and future development activities related to lunresertib. 'We are excited to enter into this worldwide license agreement with Repare for lunresertib. Based on very promising Phase 1/1b clinical data, we believe the combination of lunresertib and Debio 0123 is highly synergistic and could potentially drive rapid and deep tumor regressions,' said Bertrand Ducrey, CEO of Debiopharm. 'We believe the synthetic lethality approach of lunresertib in combination with Debio 0123 will allow us to bring this innovative precision therapy to patients with difficult to treat cancers.' Continued Prioritization of RP-3467 and RP-1664 Moving forward, Repare will remain focused on the advancement of its two ongoing Phase 1 clinical trials, POLAR and LIONS. The POLAR clinical trial is a multicenter, open-label, dose-escalation Phase 1 clinical trial designed to investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of RP-3467, a small molecule inhibitor of polymerase theta (Polθ) that is a synthetic lethality target associated with BRCA mutations and other genomic alterations, alone or in combination with olaparib in adults with locally advanced or metastatic epithelial ovarian cancer, metastatic breast cancer, metastatic castration-resistant prostate cancer, or pancreatic adenocarcinoma. Topline safety, tolerability and early efficacy data from the Phase 1 POLAR clinical trial of RP-3467 alone and in combination with olaparib is expected in the third quarter of 2025. The LIONS clinical trial is a first-in-human, multicenter, open-label Phase 1 clinical trial designed to investigate safety, pharmacokinetics, pharmacodynamics and the preliminary efficacy of RP-1664, a first-in-class, highly selective, oral inhibitor of Polo-like kinase 4 (PLK4) that is a synthetic lethality target associated with TRIM37 overexpression. Initial topline safety, tolerability and early efficacy data from the Phase 1 LIONS clinical trial of RP-1664 is expected in the fourth quarter of 2025. About Repare Therapeutics Inc. Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-3467, a Phase 1 Polθ ATPase inhibitor and RP-1664, a Phase 1 PLK4 inhibitor. For more information, please visit and follow @Reparerx on X (formerly Twitter) and LinkedIn. Debiopharm's Commitment to Patients Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit Follow us, we are on LinkedIn. Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995 and securities laws in Canada. All statements in this press release other than statements of historical facts are 'forward-looking statements. These statements may be identified by words such as 'aims,' 'anticipates,' 'believes,' 'could,' 'estimates,' 'expects,' 'forecasts,' 'goal,' 'intends,' 'may,' 'plans,' 'possible,' 'potential,' 'seeks,' 'will' and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company's out-license of lunresertib to Debiopharm, including the potential benefits of the transaction and the achievement and receipt of milestone payments and royalties under the license agreement; the Company's anticipated cash runway; the timing, progress and results of the Company's ongoing Phase 1 LIONS and POLAR clinical trials; and the potential, tolerability, efficacy and clinical progress of the Company's product candidates, including the potential of lunresertib to treat patients with difficult-to-treat solid tumors as a monotherapy or in combination with Debio 0123. These forward-looking statements are based on the Company's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the impacts of macroeconomic conditions, including tariffs and other trade policies, the conflict in Ukraine and the conflict in the Middle East, fluctuations in inflation and uncertain credit and financial markets, on the Company's business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company's ability to realize the benefits of its collaboration and license agreements; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ('SEC') and the Québec Autorité des Marchés Financiers ("AMF") on March 3, 2025, and in other filings made with the SEC and AMF from time to time, including the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. For more information, please visit and follow Repare on X (formerly Twitter) at @RepareRx and on LinkedIn at
